References
- Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification of tumors of the nervous system. 4th ed. Lyon: IARC; 2007. pp 187–192.
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp 171–174.
- Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008;132:1830–1834.
- Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570–4574.
- Nayak L, Hedvat C, Rosenblum MK, et al. Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol 2011;13:525–529.
- Wang JQ, Jeelall YS, Beutler B, et al. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med 2014;211:413–426.
- Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
- Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012;367:826–833.
- Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121:2051–2058.
- Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101–105.
- Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013;6:e139.
- Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2014;28:719–720.
- Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies. Immunol Rev 2012;246:359–378.
- Staudt LM. Oncogenic activation of NF-kB. Cold Spring Harb Perspect Biol 2010;2:a000109.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275–282.
- Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012;18:5203–5211.
- Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494–5502.
- Lin CH, Kuo KT, Chuang SS, et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous origin and peripheral nodal origin. Clin Cancer Res 2006;12:1152–1156.
- Hattab EM, Martin SE, Al-Khatib SM, et al. Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. Mod Pathol 2010;23: 235–243.
- Preusser M, Woehrer A, Koperek O, et al. Primary central nervous system lymphoma: a clinicopathological study of 75 cases. Pathology 2010;42:547–552.